Endocrinol Metab.  2020 Mar;35(1):192-193. 10.3803/EnM.2020.35.1.192.

Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)

• Rhee SY

• KMID: 2471736
• DOI: http://doi.org/10.3803/EnM.2020.35.1.192

Abstract

No abstract available.

MeSH Terms

Adult*
Humans
Insulin*
Insulin

Reference

1. Jang HN, Yang YS, Lee SO, Oh TJ, Koo BK, Jung HS. Favorable glycemic control with once-daily insulin degludec/insulin aspart after changing from basal insulin in adults with type 2 diabetes. Endocrinol Metab (Seoul). 2019; 34:382–389. PMID: 31884738.

2. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002; 25:275–278. PMID: 11815495.

3. Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, et al. Benefits of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016; 39:2026–2035. PMID: 27527848.

4. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394:121–130. PMID: 31189511.